Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pre-Eclampsia | 3 | 2012 | 53 | 0.840 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2019 | 268 | 0.730 |
Why?
|
| Kidney Failure, Chronic | 3 | 2017 | 518 | 0.640 |
Why?
|
| Hypertension | 7 | 2017 | 906 | 0.550 |
Why?
|
| Cardiovascular Diseases | 5 | 2019 | 1013 | 0.540 |
Why?
|
| Blood Pressure | 8 | 2019 | 804 | 0.520 |
Why?
|
| Antihypertensive Agents | 5 | 2017 | 339 | 0.510 |
Why?
|
| Complement Pathway, Alternative | 1 | 2013 | 1 | 0.460 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2013 | 4 | 0.460 |
Why?
|
| Complement C3 | 1 | 2013 | 7 | 0.460 |
Why?
|
| Kidney Glomerulus | 1 | 2013 | 30 | 0.440 |
Why?
|
| Death, Sudden | 1 | 2012 | 8 | 0.430 |
Why?
|
| Renal Dialysis | 1 | 2012 | 259 | 0.350 |
Why?
|
| Placentation | 1 | 2008 | 4 | 0.340 |
Why?
|
| Placenta | 1 | 2008 | 63 | 0.320 |
Why?
|
| Glomerular Filtration Rate | 6 | 2019 | 287 | 0.320 |
Why?
|
| Patient Care Planning | 1 | 2006 | 53 | 0.270 |
Why?
|
| Apolipoproteins | 2 | 2016 | 196 | 0.230 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 247 | 0.220 |
Why?
|
| Heart Failure | 3 | 2017 | 568 | 0.220 |
Why?
|
| Cause of Death | 3 | 2017 | 220 | 0.210 |
Why?
|
| Humans | 16 | 2019 | 29093 | 0.200 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 546 | 0.200 |
Why?
|
| Kidney Tubules | 1 | 2019 | 25 | 0.180 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 666 | 0.180 |
Why?
|
| Pregnancy | 3 | 2012 | 815 | 0.180 |
Why?
|
| Adenine Phosphoribosyltransferase | 1 | 2018 | 3 | 0.170 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2018 | 3 | 0.170 |
Why?
|
| Urolithiasis | 1 | 2018 | 7 | 0.170 |
Why?
|
| Nephritis, Interstitial | 1 | 2018 | 9 | 0.170 |
Why?
|
| Kidney Calculi | 1 | 2018 | 25 | 0.170 |
Why?
|
| Female | 11 | 2019 | 18164 | 0.160 |
Why?
|
| Acute Coronary Syndrome | 2 | 2017 | 175 | 0.160 |
Why?
|
| Nitrates | 1 | 2017 | 25 | 0.150 |
Why?
|
| Myocardial Infarction | 2 | 2017 | 412 | 0.140 |
Why?
|
| Aged | 8 | 2019 | 9487 | 0.140 |
Why?
|
| Dietary Supplements | 1 | 2017 | 170 | 0.140 |
Why?
|
| Risk Factors | 4 | 2019 | 3531 | 0.130 |
Why?
|
| Middle Aged | 8 | 2019 | 10829 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2016 | 239 | 0.120 |
Why?
|
| Antigen-Antibody Complex | 1 | 2013 | 2 | 0.110 |
Why?
|
| Microscopy, Electron | 1 | 2013 | 25 | 0.110 |
Why?
|
| Male | 8 | 2019 | 17807 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 81 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 3717 | 0.110 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2012 | 15 | 0.110 |
Why?
|
| Calcium Carbonate | 1 | 2012 | 7 | 0.110 |
Why?
|
| Blood Pressure Determination | 3 | 2017 | 94 | 0.110 |
Why?
|
| Exercise | 1 | 2017 | 591 | 0.110 |
Why?
|
| Biopsy | 1 | 2013 | 241 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 2108 | 0.100 |
Why?
|
| Incidence | 2 | 2017 | 1119 | 0.100 |
Why?
|
| Serum Amyloid P-Component | 1 | 2008 | 2 | 0.090 |
Why?
|
| Galectins | 1 | 2008 | 6 | 0.090 |
Why?
|
| Angiogenic Proteins | 1 | 2008 | 9 | 0.090 |
Why?
|
| Pregnancy Proteins | 1 | 2008 | 10 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2008 | 61 | 0.080 |
Why?
|
| Age Factors | 2 | 2016 | 1108 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2008 | 41 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2008 | 72 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2008 | 100 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 232 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 787 | 0.070 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 102 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 163 | 0.070 |
Why?
|
| Adolescent | 1 | 2013 | 3254 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 436 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 637 | 0.060 |
Why?
|
| Comorbidity | 1 | 2006 | 540 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 641 | 0.060 |
Why?
|
| Antimetabolites | 1 | 2018 | 10 | 0.040 |
Why?
|
| Allopurinol | 1 | 2018 | 6 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2006 | 3111 | 0.040 |
Why?
|
| African Americans | 2 | 2016 | 1373 | 0.040 |
Why?
|
| Reference Standards | 1 | 2017 | 30 | 0.040 |
Why?
|
| Nitrites | 1 | 2017 | 20 | 0.040 |
Why?
|
| Beta vulgaris | 1 | 2017 | 11 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3099 | 0.040 |
Why?
|
| Physical Endurance | 1 | 2017 | 31 | 0.040 |
Why?
|
| Systole | 1 | 2017 | 87 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 246 | 0.040 |
Why?
|
| Critical Care | 1 | 2017 | 114 | 0.040 |
Why?
|
| Oxygen | 1 | 2017 | 139 | 0.040 |
Why?
|
| Inflammation | 1 | 2019 | 507 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 709 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 289 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2017 | 278 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 863 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 464 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2014 | 251 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 2001 | 0.030 |
Why?
|
| Antacids | 1 | 2012 | 3 | 0.030 |
Why?
|
| Cognition | 1 | 2016 | 526 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 1305 | 0.030 |
Why?
|
| Stroke | 1 | 2017 | 545 | 0.030 |
Why?
|
| Gestational Age | 1 | 2012 | 96 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 52 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2012 | 501 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 1218 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 369 | 0.020 |
Why?
|
| United States | 1 | 2017 | 3630 | 0.020 |
Why?
|
| Brain | 1 | 2016 | 930 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 1379 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 2019 | 0.020 |
Why?
|
| Adult | 1 | 2012 | 8420 | 0.010 |
Why?
|